Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations

European Journal of Clinical Pharmacology

Volumn 70, Issue 9, 2014, Pages 1059-1071

  Rocha, José Francisco ^a   Falcão, Amílcar ^b   Santos, Ana ^a   Pinto, Roberto ^a,c   Lopes, Nelson ^a   Nunes, Teresa ^a   Wright, Lyndon C ^a   Vaz Da Silva, Manuel ^a,c   Soares Da Silva, Patrício ^a,c  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Carbidopa; COMT inhibitors; Entacapone; Levodopa; Opicapone; Pharmacokinetics

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; ENTACAPONE; LEVODOPA; OPICAPONE; PLACEBO; ANTIPARKINSON AGENT; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE INHIBITOR; NITRILE; OXADIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NORMAL HUMAN; PARALLEL DESIGN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; BLOOD; DRUG ADMINISTRATION; DRUG INTERACTION; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTIPARKINSON AGENTS; AREA UNDER CURVE; CATECHOL O-METHYLTRANSFERASE; CATECHOL O-METHYLTRANSFERASE INHIBITORS; CATECHOLS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; OXADIAZOLES; YOUNG ADULT;

EID: 84906276703     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1701-2     Document Type: Article

References (32)

1. Morgan JC, Sethi KD (2006) Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs 11(3):403-417 (Pubitemid 44386366)
2. Schapira AH, Emre M, Jenner P, Poewe W (2009) Levodopa in the treatment of Parkinson's disease. Eur J Neurol: Off J Eur Fed Neurol Soc 16(9):982-989. doi:10.1111/j.1468-1331.2009.02697.x
3. Dingemanse J (2000) Issues important for rational COMT inhibition. Neurology 55(11 Suppl 4):S24-S27, discussion S28-32
4. Palma PN, Bonifácio MJ, Almeida L, Soares-Da-Silva P (2007) Restoring dopamine levels. In: Simth HJ, Simons C, Sewell RDE (eds) Protein misfolding in neurodegenerative diseases: mechanisms and therapeutic strategies. CRC Press, pp415-445
5. Gomes P, Soares-da-Silva P (1999) Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology 38(9):1371-1380 (Pubitemid 29333153)
6. Gervas JJ, Muradas V, Bazan E, Aguado EG, de Yebenes JG (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33(3):278-282 (Pubitemid 13155756)
7. Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 21(6):584-588. doi:10.1002/ana.410210610 (Pubitemid 17081194)
8. Wade LA, Katzman R (1975) 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 17(1):131-136
9. Olanow CW, Stocchi F (2004) COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 62(1 Suppl 1):S72-S81 (Pubitemid 38082855)
10. Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silva P (2007) Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev 13:352-379. doi:10.1111/j.1527-3458.2007.00020.x (Pubitemid 47481088)
11. Lang AE, Lees A (2002) Management of Parkinson's disease: an evidence-based review. Mov Disord 17(Suppl 4):S45-S51
12. Brooks DJ (2004) Safety and tolerability of COMT inhibitors. Neurology 62(1 Suppl 1):S39-S46
13. Kiss LE, Ferreira HS, Torrao L, Bonifacio MJ, Palma PN, Soares-da-Silva P, Learmonth DA (2010) Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 53(8):3396-3411
14. Palma PN, Bonifácio MJ, Loureiro AI, Soares-da-Silva P (2012) Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem 33(9):970-986
15. Bonifácio MJ, Torrão L, Loureiro AI, Wright LC, Soares-da-Silva P (2012) Opicapone: characterization of a novel peripheral long-acting catechol-O-methyltransferase inhibitior. Parkinsonism Relat Disord 18(S2):S125
16. Bonifácio MJ, Sutcliffe JS, Torrão L, Wright LC, Soares-da-Silva P (2012) Brain and peripheral levodopa pharmacokinetics in the Cynomolgus monkey following administration of opicapone, a novel catechol-O-methyltransferase inhibitor. Parkinsonism Relat Disord 18(S2):S125
17. Almeida L, Rocha J-F, Falcão A, Palma N, Loureiro AI, Pinto R, Bonifácio M, Wright LC, Nunes T, Soares-da-Silva P (2013) Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet 52(2):139-151
18. Rocha JF, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R, Bonifacio MJ, Wright LC, Nunes T, Soares-da-Silva P (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76(5):763-775. doi:10.1111/bcp.12081
19. Ferreira JJ, Rocha JF, Falcão A, Pinto R, Nunes T, Soares-da-Silva P (2013) Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics, motor response, and erythrocyte-COMT activity in Parkinson 's patients co-administered with levodopa/dopadecarboxylase inhibitor. Mov Disord 28(Suppl 1):S154-S431
20. Ferreira JJ, Rocha JF, Santos A, Nunes T, Soares-da-Silva P (2012) The design of a double-blind, placebo- and active-controlled, multinational phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: Opicapone superiority vs. placebo and non-inferiority vs. entacapone. Mov Disord 27(Suppl 1):S118
21. Lees A, Costa R, Oliveira C, Lopes N, Nunes T, Soares-da-Silva P (2012) The design of a double-blind, placebo-controlled, multinational phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo. Mov Disord 27(Suppl 1):S127
22. Silveira P, Vaz-da-Silva M, Almeida L, Maia J, Falcão A, Loureiro AI, Torrão L, Machado R, Wright LC, Soares-da-Silva P (2003) Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. Eur J Clin Pharmacol 59:603-609 (Pubitemid 37494527)
23. Vieira-Coelho MA, Soares-da-Silva P (1996) Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol 117(3):516-520 (Pubitemid 26056861)
24. Vieira-Coelho MA, Soares-da-Silva P (1999) Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res 821(1):69-78 (Pubitemid 29219681)
25. Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, Reinikainen K (2002) Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol 54(4):363-371 (Pubitemid 35334948)
26. Keranen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikainen PJ, Rita H, Seppala L, Wikberg T (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics andmetabolismof levodopa in healthy volunteers. Clin Neuropharmacol 16(2):145-156 (Pubitemid 23090692)
27. Rouru J, Gordin A, Huupponen R, Huhtala S, Savontaus E, Korpela K, Reinikainen K, Scheinin M (1999) Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. Eur J Clin Pharmacol 55(6):461-467 (Pubitemid 29399659)
28. Kurlan R, Nutt JG, Woodward WR, Rothfield K, Lichter D, Miller C, Carter JH, Shoulson I (1988) Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 23(6):589 -595. doi:10.1002/ana.410230611
29. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN (1989) Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 25(5):523-526. doi:10.1002/ana.410250521 (Pubitemid 19136689)
30. Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62(6):905-910. doi:10.1001/archneur.62.6.905 (Pubitemid 40973452)
31. Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamaki M, Ellmen J (2012) The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations. Eur J Clin Pharmacol 68(3):281-289. doi:10.1007/s00228-011-1121-5
32. Jorga K, Banken L, Fotteler B, Snell P, Steimer JL (2000) Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone. Clin Pharmacol Ther 67(6):610-620. doi:10.1067/mcp.2000.106795 (Pubitemid 30416077)